Propanc Biopharma, Inc. (OTCMKTS:PPCB) Sees Significant Growth in Short Interest

Propanc Biopharma, Inc. (OTCMKTS:PPCB) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 200 shares, a growth of 100.0% from the February 28th total of 100 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 400 shares, the short-interest ratio is currently 0.5 days.

Propanc Biopharma Price Performance

PPCB stock traded down $0.43 during midday trading on Friday, reaching $5.25. The stock had a trading volume of 116 shares, compared to its average volume of 415. Propanc Biopharma has a twelve month low of $2.76 and a twelve month high of $222.00. The business has a fifty day simple moving average of $6.64 and a two-hundred day simple moving average of $2.32.

About Propanc Biopharma

Propanc Biopharma, Inc, a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes.